(Q35551149)

8 August 2017

1 reference

title

Small-molecule cyclin-dependent kinase modulators (English)

1 reference

8 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14528286

18 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206954

18 March 2024

author name string

Adrian M. Senderowicz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14528286

18 March 2024

language of work or name

English

0 references

publication date

1 September 2003

1 reference

8 August 2017

29 September 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14528286

full work available at URL

18 March 2024

https://www.nature.com/articles/1206954.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14528286

https://www.nature.com/articles/1206954.pdf

18 March 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206954

https://www.nature.com/articles/1206954

18 March 2024

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206954

18 March 2024

1 reference

8 August 2017

22

1 reference

8 August 2017

6609-6620

1 reference

8 August 2017

42

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1206954

8 August 2017

0 references

cites work

Proteasome inhibition: a new strategy in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Flavopiridol inhibits P-TEFb and blocks HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Regulation of cyclin D1 by calpain protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Synthesis of potent oxindole CDK2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Characterization of novel inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

21 January 2018

Cyclin D and oncogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Quinazolines as cyclin dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

AKT plays a central role in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Molecular pathology of the cell cycle in human cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Dysidiolide and related gamma-hydroxy butenolide compounds as inhibitors of the protein tyrosine phosphatase, CDC25

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Control of Cyclin D1 Expression by Antisense Oligonucleotides in Three Ovarian Cancer Cell Lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Synthesis of a novel class of cdc25A inhibitors from vitamin D3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

The role of RB in cell cycle control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

The expanding role of cell cycle regulators.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

The retinoblastoma protein binds to a family of E2F transcription factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Apoptosis and the prognostic significance of p53 mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Chemical inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Small molecule modulators of cyclin-dependent kinases for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Cyclin-dependent kinases as new targets for the prevention and treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

1 reference

7 January 2021

Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

UCN-01, a selective inhibitor of protein kinase C from Streptomyces.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

28 Use and specificity of staurosporine, UCN-O1, and calphostin C as protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Small-molecule inhibitors of cyclin-dependent kinases: molecular tools and potential therapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Inhibition of cell proliferation in head and neck squamous cell carcinoma cell lines with antisense cyclin D1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Histone acetylation and the cell-cycle in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Transcriptional repression by RB-E2F and regulation of anchorage-independent survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Synthesis, Structure−Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206954

7 January 2021

Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation

72

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206954

Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells

18 March 2024

167

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206954

Thymocyte selection in Vav and IRF-1 gene-deficient mice

18 March 2024

168

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206954

18 March 2024

Identifiers

1 reference

Dimensions Publication ID

8 August 2017

0 references

1 reference